Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by mercedesmanon Jun 01, 2022 11:21am
167 Views
Post# 34723373

RE:Small Mention at Bloomberg

RE:Small Mention at Bloomberg
PezDalatoYou wrote: Apologies if this was posted before. https://www.bloomberg.com/press-releases/2022-04-19/global-dialysis-devices-market-to-progress-at-a-substantial-cagr-of-4-84-reaching-usd-94-30-billion-by-2026-asserts


 Dialysis Devices Market Company and Product Profiles 9.1 Fresenius Medical Care 9.2 B. Braun Melsungen AG 9.3 Nipro Corporation 9.4 Dialife SA 9.5 Baxter 9.6 Cantel Medical Corporation 9.7 NIKKISO CO. LTD. 9.8 Asahi Kasei Medical 9.9 NxStage Medical, Inc 9.10 Infomed SA
Other salient points:

 North America is predicted to register the fastest growth in the Dialysis market 
 In terms of revenue North America currently holds the Global Dialysis market share and is expected to remain constant during the forecast period. This domination is owing is due to the rising prevalence of kidney disorders, the rising population of patients suffering from lifestyle disorders such as obesity and hypertension leading to a high surge in Dialysis Devices market growth. Moreover, extensive efforts in product developmental activities and the growing popularity of home-based dialysis devices are further expected to drive the Dialysis Devices market in the North American region. 
 COVID-19 pandemic had a profound impact on elective and non-urgent surgeries across the countries. The Dialysis Devices market is primarily affected by the outbreak of the COVID-19 pandemic. The government imposed lockdowns to curb the spread of the virus leading to restrictions on movement and a decrease in regular check-ups leading to a decrease in the Dialysis Devices market growth. 
 Key Dialysis Companies -  Fresenius Medical Care, B. Braun Melsungen AG, Nipro Corporation, Dialife SA, Baxter, Cantel Medical Corporation, NIKKISO CO., LTD, Asahi Kasei Medical, NxStage Medical, Inc. Infomed SA, Medtronic, Anjue Medical Equipment Co., Ltd., Dialco Medical Inc., SWS Hemodialysis Care Co., Ltd, TORAY MEDICAL CO, LTD., Trivitron Healthcare,  BLT Biolight Meditech, QUANTA Dialysis Technologies (oddly we are connected directly or indirectly to almost every highlighted name)
 The Global Dialysis Devices market was valued at USD 71.00 billion in 2020 , growing at a CAGR of 4.84% during the forecast period from 2021 to 2026 to reach USD 94.30 billion by 2026.
________________________________________________

Having acknowledged that Covid has slowed down the growth of the Dialysis market (by definition temporarily given gorwth profile), I wonder if their analysis addresses the fact that Covid is likely to have resulted in an increase in AKI, and therefore an increasing need for dialysis, and the need for more PD and HHD, in the long run ?

I don't feel like popping for the cost of the Report, to find out...but I think that I already know the answer.

MM

<< Previous
Bullboard Posts
Next >>